Worldwide, there was a large increase in the average total number of patients per clinical drug trial from 2019 to 2023. This statistic shows the average number of patients per clinical drug trial started worldwide from 2012 to 2023.

Worldwide, there was an increase in the average number of subjects per clinical drug trial for each phase between 2019 and the end of 2020. This statistic shows the average number of subjects per clinical drug trial started worldwide between 2015 and November 2020, by trial phase.

This statistic displays the average number of patients per clinical trial in selected countries in Europe from 2005 to 2011. In this period, Germany had the largest number of patients entering clinical trials with an average of *** patients per clinical trial.

In the pandemic years 2020 to 2023, the average number of sites per clinical drug trial worldwide was relatively stable, with of 18 in 2021. This statistic shows the average total number of sites per clinical drug trial worldwide from 2012 to 2023.

Clinical studies are an important part of drug development globally. The number of registered clinical trials has increased significantly recently. As of June 13, 2025, there were over *** thousand clinical studies registered globally. The number of clinical studies has increased significantly since there were just ***** registered in 2000. In general, clinical trials have grown more complex in recent years and remain vital for the research and development of new drugs and products. Research and development Research and development are an essential part of pharmaceutical companies and includes drug development and product development. Among all industry sectors, the pharmaceutical industry spends the largest percentage of their revenue on research and development. Many companies are active in pharmaceutical research and development globally. It is projected Swiss company Roche will remain one of the largest research and development spenders among pharmaceutical companies in the near future. Clinical studies globally Most clinical studies occurring globally are held in countries outside the U.S. Many clinical trials performed outside the U.S. and EU are done so because it is often easier and cheaper to conduct trials in other locations. Success rates for clinical trials depend heavily on the stage of the trial and the drugs or products being developed. Recent data suggested that only around ** percent of drugs make it from phase II to phase III.

Clinical Trials Management System Market size was valued at USD 1177.91 Million in 2023 and is projected to reach USD 3294.64 Million by 2031, growing at a CAGR of 13.72% from 2024 to 2031.

Key Market Drivers: • Growing Complexity of Clinical Trials: The increasing complexity of clinical trials necessitates sophisticated management systems. According to the United States Food and Drug Administration (FDA), the average number of endpoints in pivotal trials for new medications approved in 2022 was 8.2, up from 5.7 in 2012, indicating a 44% increase in trial complexity over ten years. • Increasing Number of Clinical Trials Globally: The increasing number of clinical trials worldwide is a significant driver of the CTMS market. According to ClinicalTrials.gov, the number of registered studies grew from 329,724 in 2020 to over 425,000 by early 2024, a 29% increase in four years. • Increasing Adoption of Decentralized and Virtual Clinical Trials: The COVID-19 pandemic has expedited the use of decentralized and virtual clinical trials, creating a demand for improved CTMS systems. According to a Tufts Center for the Study of Drug Development report from 2023, 60% of clinical trials included at least one decentralized element, up from 33% in 2020.

Clinical Trial Management System Market Outlook 2032

The global Clinical Trial Management System Market size was USD 1.94 Billion in 2023 and is projected to reach USD 6.52 Billion by 2032, expanding at a CAGR of 14.4% during 2024–2032. The increasing complexity of clinical trials and the growing need for efficient data management solutions drives the market.



Increasing emphasis on decentralized clinical trials propels the market. Innovations in remote monitoring and patient management technologies enable trials to extend beyond traditional settings, reducing patient burden and expanding recruitment pools. This shift necessitates robust CTMS platforms capable of supporting complex, multi-location trials, ensuring data integrity and regulatory compliance across diverse geographies.

Surging interest in cloud-based CTMS solutions transforms the market landscape. These platforms offer scalability, enhanced security, and cost-effectiveness, facilitating seamless collaboration between stakeholders globally. The ability to rapidly deploy updates and integrate with other eClinical tools streamlines trial management processes, driving efficiency in study operations.

• In July 2023, RealTime Software Solutions, LLC, a prominent supplier of cloud-based software for the clinical research sector, declared its purchase of Devana Solutions, LLC, a pioneering SaaS company focused on workflow and analytics solutions for clinical trials. This acquisition represents a strategic step toward offering the market's most extensive and sophisticated end-to-end platform for research sites.

Increasing prioritization of patient-centric strategies in clinical research underscores the need for advanced CTMS capabilities. Systems that support direct patient engagement, remote consent, and real-time data access empower participants and improve retention rates. This trend toward patient-centeredness demands CTMS solutions that are flexible and user-friendly, enhancing the overall trial experience for participants.

<span lang=&q

ObjectiveNI margins have to be chosen appropriately to control the risk of degradation of treatment effects in non-inferiority (NI) trials. We aimed to study whether the current choice of NI margins protects sufficiently against a degradation of treatment effect on an average.Study Design and SettingNI trials reflecting current practice were assembled and for each trial, the NI margin was translated into a likelihood of degradation. The likelihood of degradation was calculated as the conditional probability of a treatment being harmful given that it is declared non-inferior in the trial, using simulation. Its distribution among the NI trials was then studied to assess the potential risk of degradation.ResultsThe median (lower/upper quartile) NI margin among 112 binary outcome NI trials corresponded to an odds ratio of 0.57(0.45, 0.66), while among 38 NI trials with continuous outcome, to a Cohen’s d of −0.42(−0.54, −0.31) and a hazard ratio of 0.82(0.73, 0.86) among 24 survival outcome NI trials. Overall, the median likelihood of degradation was 56% (45%, 62%).ConclusionOnly two fifths of the current NI trials had a likelihood of degradation lower than 50%, suggesting that, in majority of the NI trials, there is no sufficient protection against degradation on an average. We suggest a third hurdle for the choice of NI margins, thus contributing a sufficient degree of protection.

The following is an information retrieval test collection that contains:

• 204,855 publicly available clinical trails was crawled from ClinicalTrials.gov.
• 60 topics made up of three types: patient case descriptions, patient case summaries and assessor provided ad-hoc queries, totalling an average of 10.2 queries per topic.
• 4,000 assessor provided relevance assessment for topic, trial pairs.

Further details about the test collection can be found in the following publication:

B. Koopman and G. Zuccon. A test collection for matching patient trials. In Proceedings of the 39th annual international ACM SIGIR conference on research and development in information retrieval, Pisa, July 2016.

Between 2019 and the end of 2020, there was a 40 percent decrease in the average number of sites per clinical drug trial worldwide. This statistic shows the average number of sites per clinical drug trial started worldwide from 2015 to 2020, by trial phase.

GlobalData's clinical trial report, “Down Syndrome Disease – Global Clinical Trials Review, H2, 2020" provides an overview of Down Syndrome Clinical trials scenario. This report provides top line data relating to the clinical trials on Down Syndrome. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database – Pharma – Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. Read More

The size of the Global Neurology Clinical Trials Market was valued at USD XX Million in 2023 and is projected to reach USD XXX Million by 2032, with an expected CAGR of 4.35% during the forecast period. Global Neurology Clinical Trials is in steady growth due to the high incidence of neurological disorders, the development of medical research activities, and the need for better treatments. Neurodegenerative disorders like Alzheimer’s, Parkinson’s, multiple sclerosis, epilepsy, and migraine are increasing in occurrence with the increased average global life expectancy thus the demand for neurotherapeutic interventions. Clinical trials are necessary not only to introduce new medications to the big variety of patients suffering from these disorders but also to present new approaches in drug delivery, medical devices, and gene therapy. The market is also growing because of positive changes in trial approaches such as digital health, remote monitoring, and design. These changes make clinical trial more efficient, less costly and enhance patient enrollment and retention. Global top pharmaceuticals and CROs as well as academic centers are expanding their neurology trial portfolios and exploring the roles of precision medicine, biomarkers, and personalized treatments. However there has been enhancement in the interest in neurological conditions, news cience research in the neurosciences is encourage the influx of investment in the clinical trials for the neurology clinical trials. However, there are numerous issues like high costs, very long trial periods, and several government restraints; however, a greater number of markets are expected to increase because advances in cure and technology offer more chance to clinical research. Recent developments include: In May 2022 Alzamed announced the initiation of Phase II A multiple ascendung dose clinical trail for AL001 treatment of Dementia related to Alzheimer's., In March 2022, AbbVie announced plans to present 30 abstracts demonstrating its breadth of Neuroscience Portfolio and Pipeline, including continued migraine treatment research across the spectrum of the disease, commitment to patients with advanced Parkinson's disease, and new studies in spasticity and cervical dystonia at the at American Academy of Neurology (AAN) 2022 Annual Meeting.. Key drivers for this market are: Increasing number of companies Conducting Clinical Trials in Neurology, Rising Prevalence of Various Neurological Diseases; Increasing R&D Investments and Government Funding Towards Neurological Research. Potential restraints include: Stringent Regulatory Demand, High Failure Rates and Increasing Cost of Clinical Trials. Notable trends are: Alzheimer’s Disease by Indication is Expected to Grow Over the Forecast Period.

GlobalData’s clinical trial report, “Huntington Disease – Global Clinical Trials Review, 2022″ provides an overview of Huntington Disease Clinical trials scenario. This report provides top line data relating to the clinical trials on Huntington Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database – Pharma – Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. Read More

GlobalData’s clinical trial report, “Obsessive-Compulsive Disorder – Global Clinical Trials Review, 2022″ provides an overview of Obsessive-Compulsive Disorder Clinical trials scenario. This report provides top line data relating to the clinical trials on Obsessive-Compulsive Disorder. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database – Pharma – Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. Read More

GlobalData’s clinical trial report, “Coronavirus Disease 2019 (COVID-19) Global Clinical Trials Review, H1, 2020″ provides an overview of Coronavirus Disease 2019 (COVID-19) Clinical trials scenario. This report provides top line data relating to the clinical trials on Coronavirus Disease 2019 (COVID-19). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database – Pharma – Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. Read More

GlobalData's clinical trial report, “Neutropenia – Global Clinical Trials Review, H1, 2021" provides an overview of Neutropenia Clinical trials scenario. This report provides top line data relating to the clinical trials on Neutropenia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database – Pharma – Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. Read More

GlobalData's clinical trial report, “Cervical Cancer Global Clinical Trials Review, H1, 2020" provides an overview of Cervical Cancer Clinical trials scenario. This report provides top line data relating to the clinical trials on Cervical Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database – Pharma – Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. Read More

GlobalData's clinical trial report, “Ovarian Cancer Global Clinical Trials Review, H1, 2020" provides an overview of Ovarian Cancer Clinical trials scenario. This report provides top line data relating to the clinical trials on Ovarian Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database – Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. Read More

BackgroundThe quality of colonoscopies performed by primary care physicians (PCPs) is unknown.ObjectiveTo determine whether PCP colonoscopists achieve colonoscopy quality benchmarks, and patient satisfaction with having their colonoscopy performed by a primary care physician.DesignProspective multi-center, multi-physician observational study. Colonoscopic quality data collection occurred via completion of case report forms and pathological confirmation of lesions. Patient satisfaction was captured by a telephone survey.SettingThirteen rural and suburban hospitals in Alberta, Canada.MeasurementsProportion of successful cecal intubations, average number of adenomas detected per colonoscopy, proportion of patients with at least one adenoma, and serious adverse event rates; patient satisfaction with their wait time and procedure, as well as willingness to have a repeat colonoscopy performed by their primary care endoscopist.ResultsIn the two-month study period, 10 study physicians performed 577 colonoscopies. The overall adjusted proportion of successful cecal intubations was 96.5% (95% CI 94.6–97.8), and all physicians achieved the adjusted cecal intubation target of ≥90%. The average number of ademonas detected per colonoscopy was 0.62 (95% CI 0.5–0.74). 46.4% (95% CI 38.5–54.3) of males and 30.2% (95% CI 22.3–38.2) of females ≥50 years of age having their first colonoscopy, had at least one adenoma. Four serious adverse events occurred (three post polypectomy bleeds and one perforation) and 99.3% of patients were willing to have a repeat colonoscopy performed by their primary care colonoscopist.LimitationsTwo-month study length and non-universal participation by Alberta primary care endoscopists.ConclusionsPrimary care physician colonoscopists can achieve quality benchmarks in colonoscopy. Training additional primary care physicians in endoscopy may improve patient access and decrease endoscopic wait times, especially in rural settings.

This statistic shows the estimated average per-patient biopharmaceutical clinical trial costs in the United States in 2013, by selected condition. In that year the cost per patient for clinical trials for new medicines related to oncology were estimated to be around ****** dollars.